Johnson & Johnson (J&J) has announced the launch of Varipulse Pro in Europe following CE-mark approval, advancing its pulsed field ablation (PFA) portfolio with a new pulse sequence that marks the “next evolution” of the company’s Varipulse platform, and is designed to improve procedural efficiency while reinforcing its established safety and effectiveness profiles.
According to J&J, Varipulse Pro introduces a new pulse sequence with a lower temperature profile and ablation that is five times faster than the previous sequence, while achieving equivalent lesions. Varipulse Pro also integrates “seamlessly” with the Carto 3 system, utilising advanced mapping capabilities, including tissue proximity indicators for precise lesion delivery.
With initial cases performed under the VARIPURE multicentre, prospective, post-market follow-up study, the company notes in a press release that it is committed to generating rigorous evidence through VARIPURE and additional clinical studies during the commercial phase of this European launch.
“In our early experience, Varipulse Pro has been exceptionally smooth and easy to use,” said Tom De Potter (Onze-Lieve-Vrouwziekenhuis [OLV] Hospital, Aalst, Belgium). “The speed is particularly striking and contributes to more efficient procedures without compromising precision. The integration with Carto mapping and intracardiac echocardiography [ICE] facilitate accurate positioning, and consistent lesion delivery, contributing to a very positive procedural experience.”
“The introduction of Varipulse Pro in Europe reflects our commitment to advancing our PFA platforms through continuous innovation, enhancing procedural experience while maintaining the consistency and precision physicians expect from the Varipulse platform,” added Michael Bodner, company group chair of electrophysiology and neurovascular at J&J MedTech. “This launch demonstrates our dedication to continuously evolving PFA technologies based on real-world learnings and our scientific expertise, supporting physicians to deliver high-quality care and improved patient outcomes.”
J&J will feature the Varipulse Pro platform this month at the European Heart Rhythm Association (EHRA) annual meeting (12–14 April, Paris, France) via live case demonstrations, hands-on training sessions, and professional education. In addition, 12-month interim results from the ongoing VARIPURE study evaluating PFA with the Varipulse platform will be presented at the 2026 PFA Summit (11 April, Paris, France) by Daniel Scherr (Medical University of Graz, Graz, Austria).
